Positive Aerin Medical AERWAY Study Results Published Showing Effectiveness of VivAer® For Nasal Obstruction Patients with Nasal Valve Collapse

Aerin Medical, Inc., a company dedicated to providing Ear Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal airway conditions, today announced the publication of the AERWAY study showing the safety and efficacy of VivAer® for treating patients with nasal airway obstruction (NAO) due to nasal valve collapse (NVC).

In the study, published in the Journal of Otolaryngology and Rhinology, patients experienced significant nasal obstruction symptom improvements at three months following treatment. The AERWAY study adds to a growing body of evidence supporting the safety and efficacy of VivAer.

“Nasal valve collapse is a common problem for the 20 million Americans suffering from nasal airway obstruction, but treatment options have historically been limited for otolaryngologists (ENT physicians),” said William Yao, M.D., the study’s principal investigator from the Department of Otorhinolaryngology – Head and Neck Surgery at McGovern Medical School at The University of Texas Health Science Center at Houston. “For patients who don’t respond to medications, temporary aids like breathing strips may not be practical, and traditional surgical procedures in the operating room have had a limited role. The results of this study showed that temperature-controlled radiofrequency energy could be a reliable and effective treatment.”

The AERWAY study, a prospective, multi-center single-arm trial, enrolled 122 adult patients with severe or extreme Nasal Obstruction Symptom Evaluation (NOSE) scores, for whom NVC was a primary or significant contributor. Data from the AERWAY study show that patients treated with VivAer experienced significant symptom improvements as well as high rates of satisfaction three months following treatment. Among the study population:

  • A significant improvement of 59% was observed in mean total NOSE scores from baseline to 3 months (a decrease from 80.3 to 32.9, respectively; p<0.001).
  • 91.6% of patients responded to treatment, demonstrating either a 20% improvement in total NOSE score relative to baseline or at least one severity category improvement in their NOSE score.
  • 87.3% of patients treated indicated they would recommend VivAer to a friend.

This study will continue to follow up with the patients through two years to evaluate the durability of the procedure’s effects, but the authors noted that three-month results have been shown to be predictive of long-term outcomes in other studies.

“Aerin Medical is committed to working closely with the otolaryngology community and societies to build strong clinical evidence around the use of non-invasive solutions for chronic nasal airway conditions,” said Matt Brokaw, CEO of Aerin Medical. “We appreciate the efforts of dozens of physician investigators involved in clinical trials demonstrating the significant benefits of our products and addressing the growing interest in treating the lateral nasal wall in appropriate patients.”

NAO can take a heavy toll on daily life. The most common symptoms include nasal congestion or stuffiness, trouble breathing through the nose, trouble sleeping, and difficulty breathing well during exercise or exertion. NVC contributes to nasal obstruction for 73% of highly symptomatic patients,1 but is often under-diagnosed and left untreated.

VivAer offers ENT physicians a unique treatment modality that remodels tissue in the nasal valve.


Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy